THE NSW government yesterday
confirmed it had secured supplies
of an oral cannabis-based medicine
called Epidiolex from British firm
GW Pharmaceuticals.
The product, an investigational
drug that has not been approved
by any regulatory agency, will be
offered to 40 juvenile patients
under a compassionate access
scheme administered separately
to previously announced trials for
medicinal cannabis (PD 29 Feb).
Epidiolex is an oral formulation
of pure cannabidiol (CBD), a nonpsychoactive
component of the
cannabis plant.
It is being trialled for severe
drug-resistant childhood epilepsy,
with the TGA authorising specialist
paediatric neurologists practicing in
NSW public hospitals to prescribe
the medication.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.